All the Drug Class Drugs
Bruton’s Tyrosine Kinase Inhibitor. acalabrutinib 100 mg. FC tab 60 X 100mg
For pts. with MCL, CLL, or SLL, recommended dosage is 100 mg taken orally approx. every 12 hours until dis. progr. or unacceptable tox.
In combin. with Bendamustine and Rituximab for pts. with previously untreated MCL, recommended dosage of this drug is 100 mg taken orally approx. every 12 hours until dis. progress. or unacceptable tox. Start this drug on Day 1 of Cycle 1 (each cycle is 28 days). Admin. bendamustine 90 mg/m2 on Days 1 and 2 and rituximab375 mg/m2 on Day 1 of Cycle 1 and continue for a total of 6 cycles. Pts. achieving a response (PR or CR) after the first 6 cycles may receive maint. rituximab on Day 1 of every other cycle for a max. of 12 additional doses, starting on Cycle 8 up to Cycle 30 .
In combination with Obinutuzumab for pts. with previously untreated CLL or SLL, recommended dosage of this drug is 100 mg taken orally approx.every 12 hours until dis. progress. or unacceptable tox. Start this drug at Cycle 1 (each cycle is 28 days). Start obinutuzumab at Cycle 2 for a total of 6 cycles and refer to the obinutuzumab prescr. info. for recommended dosing. Admin. this drug prior to obinutuzumab when given on the same day.
Tmt. of adult pts. with mantle cell lymphoma (MCL) who have received at least one prior ther. Tmt. of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In combin. with bendamustine and rituximab for tmt. of adult pts. with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplant. (HSCT).
C/I: Hypersens.
Bruton’s Tyrosine Kinase Inhibitor. Ibrutinib 140 mg. ORAL CAPS: 90, 120.
MCL: 560 mg (4× 140 mg caps.)×1/d.
CLL: 420 mg (3 ×140 mg caps.)×1/d.
Tmt. of adult pts. with (MCL) who have
received at least one prior ther.
This indication is based on overall
response rate.
An improv. in survival, dis.-related symp.
has not been established.
Tmt. of pts. with (CLL) who have received
at least one prior ther.
This indicat. is based on overall response
rate.
An improv. in survival, dis.-related symp.
has not been established.
C/I: None.
